CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
NCT Number: NCT07071974
The main objective of this trial is to investigate relative bioavailability of BI 456906 reference formulation (Formulation A) vs. BI 456906 test formulation (Formulation B2).
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Berlin, 13627, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Trial participants will only be included in the trial if they meet the following criteria:
Exclusion criteria
Participants will not be allowed to participate, if any of the following general criteria apply:
BI 456906 formulation A
Other names: Survodutide
BI 456906 formulation B2
Other names: Survodutide
Time frame: Up to 22 days.
Time frame: Up to 22 days.
Time frame: Up to 22 days.
Boehringer Ingelheim
Industry
Relative Bioavailability of Two BI 456906 Formulations After Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details